Table 1.
Summary of the cases of heterotopic pancreas adenocarcinoma in the duodenum found in the literature
| Case | Year | Author | Age | Sex | Location | Size (mm) | Biopsy | Preoperative tumor-specific antigen | Diagnostic approach | Lymphadenectomy | Lymph node metastasis | Heinrich classification | Chemotherapy | PFS (months) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2007 | Tison | 72 | M | 2nd | N.D | Negative | N.D | Ope (PD) | Performed (N.D) | + | N.D | N.D | N.D |
| 2 | 2007 | Kawakami | 65 | F | 2nd | 12 | Not performed | WNL | Ope (SSPPD) | The regional lymph nodes | N.D | N.D | N.D | 19 |
| 3 | 2008 | Rosok | 59 | F | Proximal | 50 | Negative | N.D | Ope (lap-D) | Not performed | − | N.D | Not performed | 36 |
| 4 | 2010 | Inoue | 75 | M | 2nd | 30 | Negative | WNL | Ope (PPPD) | The regional lymph nodes | + | III | Not performed | 72 |
| 5 | 2010 | Bini | 56 | M | 1st | N.D | Adenocarcinoma | WNL | EUS-FNA → Ope (PD) | The regional lymph nodes | − | I | Performed (N.D) | N.D |
| 6 | 2011 | Stock | 79 | F | 4th | 30 | Negative | Chromogranin-A, 53 mg/mL | Ope (D) | The regional lymph nodes | + | I | Performed (N.D) | N.D |
| 7 | 2012 | Kinoshita | 62 | F | 1st | 34 | Negative | CEA, 8.1 U/mL | Ope (PD) | The regional lymph nodes | − | I | Not performed | 12 |
| CA19-9, 66.9 U/mL | ||||||||||||||
| 8 | 2013 | Ginori | 86 | F | 1st | 30 | Not performed | N.D | Ope (subTG) | The regional lymph nodes | − | I | Not performed | N.D |
| 9 | 2013 | Alireza | 58 | M | 1st | 27 | Not performed | N.D | Ope (D) | Not performed | − | N.D | Performed (XELOX) | 18 |
| 10 | 2014 | Endo | 75 | M | 2nd | 22 | Adenocarcinoma | CEA, 55.4 U/mL | EUA-FNA → Ope (SSPPD) | N.D | N.D | I | Not performed | 60 |
| CA19-9, 54.8 U/mL | ||||||||||||||
| 11 | 2015 | Fukino | 62 | M | 4th | 15 | Negative | CA19-9, 500 U/mL | Ope (D) | N.D | N.D | IV | Performed (SP) | N.D |
| DUPAN-2, 226 U/mL | ||||||||||||||
| 12 | 2019 | Kaneko | 81 | M | 1st | 30 | Negative | WNL | Ope (DG) | The regional lymph nodes | + | I | Not performed | 18 |
| 13 | 2020 | Our case | 77 | M | 1st | 55 | Negative | CA19-9, 1130 U/mL | Ope (SSPPD) | The regional lymph nodes | + | I | Performed (TS1) | 9 |
| DUPAN-2, 5287 U/mL |
CEA carcinoembryonic antigen, CA carbohydrate antigen, DUPAN duke pancreatic monoclonal antigen, EUS-FNA endoscopic ultrasonography-guided fine-needle aspiration, N.D not dated, PFS progression-free survival, D (partial) duodenectomy, DG distal gastrectomy, TG total gastrectomy, PD pancreatoduodenectomy, PPPD pylorus-preserving pancreatoduodenectomy, SSPPD subtotal stomach-preserving pancreatoduodenectomy, SMT submucosal tumors, TS1 tegafur-gimeracil-dihydropyrimidine dehydrogenase, SP TS1+cisplatin, XELOX capecitabine+oxaliplatin, WNL within normal limits